AIAyşen Işık

Ayşen Işık

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşen Işık has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Synthesis, in silico study and cytotoxic evaluation of new benzimidazole derivatives as potential aromatase inhibitors

    by Ayşen Işık, Nour El-Huda Daoud, Kezban Uçar Çiftçi, Gulsah Congur, Ebru Nur Ay, Emine Rana Bagcı, Şennur Görgülü, Ulviye Acar Çevik, Yusuf Tutar, Yusuf Özkay, et al.

    1. Cancer is a disease caused by the uncontrolled growth and proliferation of cells [1], a secondary cause of death worldwide [2]. Although many treatment options are available today to treat the d...

  • Open Access

    Synthesis and Antimicrobial Evaluation of New Fluorophenyl Hybridized Thiazole and Thiadiazole Derivatives

    by Ayşen Işık

    In this study, novel hybrid derivatives (4a–4e) combining 1,3-thiazole and 1,3,4-thiadiazole rings containing p-fluorophenyl on the same molecule were synthesized and their structures were elucidated using 1H-NMR and 1³C-NMR spectroscopic methods. The antimicrobial activities of the compounds were evaluated on Gram-positive bacteria (Bacillus subtilis, Staphylococcus aureus), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa), and yeast species (Candida albicans, Candida krusei) using agar well diffusion and microdilution methods. In the diffusion test, the inhibition zone diameters ranged from 7.6 ± 0.4 to 12.3 ± 0.3 mm. The most notable activity was produced by compound 4e which produced inhibition zones of 12.3 ± 0.3 mm against E. coli, 12.0 ± 0.3 mm against P. aeruginosa and 12.0 ± 0.2 mm against C. albicans. Compound 4b was also highly effective against yeast strains, and its zone diameter against C. albicans was 12.0 ± 0.2 mm. Minimum inhibitory concentration (MIC) values were generally determined to be 1250 µg/mL for bacteria, and 625 µg/mL for some species, whereas all compounds exhibited an MIC value of 625 µg/mL against C. albicans and C. krusei. Therefore, the results obtained indicate that fluorophenyl hybrid thiazole-thiadiazole derivatives generally exhibit weak antimicrobial activity; however, it is predicted that these data will shed light on future modification studies in the context of structure-activity relationship (SAR).

  • Synthesis of Novel Benzimidazole Derivatives as a Carbonic Anhydrase IX (Ca IX ) Inhibitor With Anticancer Potential

    by Zeynep Deniz Şahin Inan, Hayrani Eren Bostancı, Serkan Kapancık, Ayşen Işık, Hacı Ahmet Kılıç, Ulviye Acar Çevik, Özen Özensoy Güler, Yusuf Özkay, Zafer Asım Kaplancıklı

    In the present study, a series of benzimidazole‐thiazole derivatives ( 4a – 4k ) were rationally designed and synthesized to evaluate their potential inhibitory effects on carbonic anhydrase IX (CA IX) and anticancer properties. The structural elucidation of the compounds was performed using spectroscopic techniques including 1 H NMR, 13 C NMR, and HRMS. Their cytotoxic activities were assessed on L929, HT29, MCF7, and C6 cell lines through MTT assays. Following the MTT assay, compound 4h was identified as exhibiting notable cytotoxicity against HT29, MCF7, and C6 cell lines, with IC 50 values measured at 36.6 ± 11.98, 22.8 ± 5.18, and 42.06 ± 6.58 μM, respectively. Moreover, compound 4h exhibited lower toxicity toward the L929 healthy mouse fibroblast cell line compared to the reference drug cisplatin. Flow cytometry analysis demonstrated that in cancer cell lines treated with compound 4h , the proportion of apoptotic cells was markedly higher than that of necrotic (non‐programmed dead) cells. Immunofluorescence microscopy analysis also confirmed that compound 4h had cytotoxic effects on cancer cells. According to the carbonic anhydrase IX activity results, compound 4h was found to have the highest activity.


  • A 5‐Year Survey on Multiple Targeted Benzimidazole Hybrids

    by Ayşen Işik, Ulviye Acar Çevik

    Among heterocyclic compounds, the various biological activities and the easily modifiable chemical structure of benzimidazole compounds make them important in drug development. Currently, the demand for treatments targeting multiple biological pathways is increasing. In the treatment of multifaceted diseases, drugs exhibiting multiple therapeutic effects and low toxicity are particularly advantageous. In this context, the ability of benzimidazole compounds to form hybrid structures that target multiple biological mechanisms is noteworthy. In this review, studies on the multifaceted biological activities of hybrid benzimidazole derivatives—including benzimidazole–triazole, benzimidazole–thiazole, benzimidazole–oxadiazole, benzimidazole–quinoline, benzimidazole–hydrazone, benzimidazole‐benzimidazole, benzimidazole–thiadiazole, benzimidazole–piperazine, benzimidazole‐imidazole, benzimidazole‐benzothiazole, benzimidazole–coumarin, benzimidazole–indole, benzimidazole‐Schiff base and benzimidazole‐urea reported in the literature over the past 5 years are discussed. In addition, this review also examines molecular modeling and structure–activity relationship studies to elucidate their therapeutic potential, highlighting the contribution of hybrid benzimidazole derivatives to the development of effective drugs.


  • Design, synthesis and biological evaluation of novel ketone derivatives containing benzimidazole and 1,3,4-triazole as CA inhibitors

    by Ulviye Acar Çevik, Ayşen Işık, Ravikumar Kapavarapu, Kaan Küçükoğlu, Hayrunnisa Nadaroglu, Hayrani Eren Bostancı, Yusuf Özkay, Zafer Asım Kaplancıklı


  • Yeni tiyazol-hidrazinil türevlerinin sentezi, karakterizasyonu, moleküler doking ve kolinesteraz inhibisyon çalışmaları

    by Ulviye Acar Çevi̇k, Ayşen IŞIK, İsMail Çeli̇k, Tugba Erceti̇n

    Alzheimer hastalığı (AD), beyinde asetilkolin üreten veya kullanan kolinerjik hücrelerin yıkımı veya kaybından kaynaklanmaktadır. Bundan dolayı, AD için ana tedavi stratejisi beyindeki asetilkolin seviyesini arttırmaktır. Bu çalışmada, kolinesteraz inhibitörleri olarak yeni tiyazol-hidrazinil türevlerinin sentezi gerçekleştirilmiştir. Sentezlenen bileşiklerin yapısı 1H-NMR ve 13C-NMR verileri ile aydınlatılmıştır. Sentezlenen hedef bileşiklerin asetilkolinesteraz (AChE) ve butirilkolinesteraz (BChE) inhibitör etkileri Ellman yöntemi kullanılarak değerlendirilmiştir. Moleküler doking çalışması Autodock Vina ile yapılmıştır. Sentezlenen bütün bileşiklerin AChE karşı düşük etkinlik sergilediği bulunmuştur. Sentezlenen bileşikler arasından sadece bileşik 3j seçici olarak BuChE inhibe ettiği bulunmuştur. Dokingden elde edilen verilere göre bileşik 3j, BuChE aktif sitesinde 10.0 kcal/mol etkileşim enerjisi ve Trp82 ile anahtar pi-pi staked etkileşimleri oluşturmuştur. Sonuç olarak, bu çalışma Alzheimer hastalığının tedavisinde seçici BuChE inhibitörü ajan geliştirmede yol göstericidir.

  • Open Access

    Synthesis and Molecular Docking of New N-Acyl Hydrazones- Benzimidazole as hCA I and II Inhibitors

    by Kaan Küçükoğlu, Ulviye Acar Çevik, Hayrunnisa Nadaroglu, Ismail Celik, Ayşen Işık, Hayrani Eren Bostancı, Yusuf Özkay, Zafer Asım Kaplancıklı

    Background: The carbonic anhydrases (CAs) which are found in most living organisms is a member of the zinc-containing metalloenzyme family. The abnormal levels and activities are frequently associated with various diseases therefore CAs have become an attractive target for the design of inhibitors or activators that can be used in the treatment of those diseases. Methods: Herein, we have designed and synthesized new benzimidazole-hydrazone derivatives to investigate the effects of these synthesized compounds on CA isoenzymes. Chemical structures of synthesized compounds were confirmed by 1H NMR, 13C NMR, and HRMS. The synthetic derivatives were screened for their inhibitory potential against carbonic anhydrase I and II by in vitro assay. Results: These compounds have IC50 values of 5.156-1.684 μM (hCA I) and 4.334-2.188 μM (hCA II). Inhibition types and Ki values of the compounds were determined. The Ki values of the compounds were 5.44 ± 0.14 μM-0.299 ± 0.01 μM (hCA I) and 3.699 ± 0.041 μM-1.507 ± 0.01 μM (hCA II). The synthetic compounds displayed inhibitory action comparable to that of the clinically utilized reference substance, acetazolamide. According to this, compound 3p was the most effective molecule with an IC50 value of 1.684 μM. Accordingly, the type of inhibition was noncompetitive and the Ki value was 0.299 ± 0.01 μM. Conclusion: According to the in vitro test results, detailed protein-ligand interactions of the compound 3p, which is more active against hCA I than standard azithromycin (AZM), were analyzed. In addition, the cytotoxic effects of the compounds on the L929 healthy cell line were evaluated.


  • Open Access

    Synthesis and Characterization of Novel Calix[4]arene Schiff Base Derivatives and Cytotoxicity Effect Evaluation on Cancer Cell Lines

    by Ayşen IŞIK, Kezban Uçar Çi̇fçi̇, Hayrani Eren Bostanci, Yusuf Tutar, Ahmet Koçak, Mustafa Yilmaz

    In this study, four stages were used to create brand-new p-tert-butyl-calix [4] arene Schiff base derivatives. First, p-tert-butyl-phenol and formaldehyde are reacted to create p-tert-butyl-calix [4] arene (1). In the following step, methyl bromoacetate and p-ter-butyl-calix [4] arene (1) were combined with acetone and reflux to create the p-tert-butyl-calix [4] arene diester complex (2). The third step involves reacting the diester compound (2) and hydrazine hydrate to create the p-tert-butyl-calix [4] arene hydrazinamide molecule (3). In the final stage, calix [4] arene Schiff base derivatives (4a-d) were produced in good yields by combining compound (3), p-tert-butyl-calix [4] arene hydrazinamide, and various aldehyde derivatives with reflux in EtOH. Through the use of 1H-NMR, 13C-NMR, infrared spectroscopy, and elemental analysis, the structures of produced compounds were verified. Four distinct cancer lines are linked to the antitumor activity of synthetic chemicals. (HT-29, a human colon cancer cell line, PC-3, a human prostate cancer cell line, C6, a rat glioma cell line and MCF-7, a human breast cancer cell line). Weak antitumor activity was seen in synthetic substances. However, only compound 4b was found to have potential efficacy against C6 and HT-29. It is clear that compound 4b, which has a nitro substitute on the phenyl ring, draws attention due to its increased activity.


  • Synthesis of new benzimidazole derivatives containing 1,3,4-thiadiazole: their in vitro antimicrobial, in silico molecular docking and molecular dynamic simulations studies

    by U. Acar Çevik, A. Işık, A.E. Evren, Ö. Kapusız, Ü.D. Gül, Y. Özkay, Z.A. Kaplancıklı

    A series of some new benzimidazole-1,3,4-thiadiazoles was synthesized. The structures of target substances were confirmed by using 1H-NMR and 13С-NMR spectroscopy, mass spectrometry and elemental analysis. The synthesized compounds were evaluated for antimicrobial activity against six bacterial strains namely Escherichia coli (ATCC 25922), Klebsiella pneumoniae (ATCC 13883), Pseudomonas aeruginosa (ATCC 27853), Enterococcus faecalis (ATCC 2942), Bacillus subtilis (ATCC 6633), Staphylococcus aureus (ATCC 29213)and four fungal strains namely Candida albicans (ATCC 24433), Candida krusei (ATCC 6258), Candida parapsilosis (ATCC 22019) and Candida glabrata (ATCC 9). Antimicrobial data revealed that compounds 4f and 4i with MIC of < 0.97 µg/mL were found to be most effective against E. coli. Among the studied molecules, compounds 4f and 4i showed the best antifungal activity with MIC value of 1.95 µg/mL. Additionally, docking studies were performed towards the most promising compounds 4f and 4i, in the active site of DNA gyrase revealing strong interactions. A molecular dynamics (MD) simulation analysis was also used to investigate the dynamic nature, binding interaction, and protein–ligand stability.


  • Synthesis, and docking studies of novel tetrazole-S-alkyl derivatives as antimicrobial agents

    by Ulviye Acar Çevik, Ismail Celik, Ayşen Işık, Ülküye Dudu Gül, Gizem Bayazıt, Hayrani Eren Bostancı, Yusuf Özkay, Zafer Asım Kaplancıklı

    A series of novel tetrazole-S-alkyl-piperazine derivatives were synthesized and evaluated for their antifungal activity against C. albicans (ATCC 24433), C. krusei (ATCC 6258) and C. parapsilosis (ATCC 22019) and antibacterial activity against E. coli (ATCC 25922), S. marcescens (ATCC 8100), K. pneumoniae (ATCC 13883), P. aeruginosa (ATCC 27853), E. faecalis (ATCC 2942), B. subtilis (ATCC), S. aureus (ATCC 29213), S. epidermidis (ATCC 12228). Among the synthesized compounds, 1-(4-cycylohexylpiperazin-1-yl)-2-((1-methyl-1H-tetrazol-5-yl)thio)ethan-1-one (2b) (MIC = 7.81 µg/mL) and 1-(4-(4-chlorobenzyl)piperazin-1-yl)-2-((1-methyl-1H-tetrazol-5-yl)thio)ethan-1-one (2f) (MIC = 3.90 µg/mL) displayed significant antifungal activity and compared to reference drugs voriconazole and fluconazole. Besides, compound 2b has showed also higher antibacterial activity against E. faecalis (ATCC 2942) as a reference drug azithromycin, with a MIC value of 3.90 µg/mL, and compound 2d was found to be effective against S. epidermidis (ATCC 12228) as the same reference drug, with a MIC value of 7.81 µg/mL. All the derivatives were efficiently synthesized by a two-step process. The structure of the newly synthesized compounds was elucidated by their 1H NMR, 13C NMR, LC-MS/MS, and elemental analysis. In this study, the detailed synthesis, spectroscopic and biological evaluation data are reported. Molecular docking studies of all compounds were performed with the sterol 14-alpha demethylase enzyme of C. albicans, the target enzyme of azole antifungal drugs. Graphical Abstract